GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Parp1 | increases cleavage | ISO | PARP1 (Homo sapiens) | 6480464 | CTD | Bortezomib results in increased cleavage of PARP1 protein | PMID:16617327 PMID:17659339 PMID:17898295 PMID:17898787 PMID:18223231 PMID:18723477 PMID:18790767 PMID:20110775 PMID:20383943 PMID:22262760 PMID:24291039 PMID:24333736 PMID:31540997 | Parp1 | increases cleavage | ISO | Parp1 (Mus musculus) | 6480464 | CTD | Bortezomib results in increased cleavage of PARP1 protein | PMID:29384525 | Parp1 | increases expression | ISO | PARP1 (Homo sapiens) | 6480464 | CTD | Bortezomib results in increased expression of PARP1 protein | PMID:17156654 | Parp1 | multiple interactions | ISO | PARP1 (Homo sapiens) | 6480464 | CTD | [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein] | PMID:12893773 PMID:12902978 PMID:15039284 PMID:16617327 PMID:16904634 PMID:16985072 PMID:17326159 PMID:17495969 PMID:17510429 PMID:17659339 PMID:18223231 PMID:19261616 PMID:19372569 PMID:19417023 PMID:20461078 PMID:21195056 PMID:22262760 PMID:24291039 PMID:24333736 PMID:25522274 PMID:31540997 PMID:33775688 | |
Go Back to source page | Continue to Ontology report |